Climb Bio, Inc. Price & Performance (CLYM)

Eliem Therapeutics has completed its acquisition of Tenet Medicines, securing approximately $220 million in cash and equivalents. This move positions the combined company to fund operations into 2027 and advance TNT119, an anti-CD19 antibody, into Phase 2 trials for multiple autoimmune diseases later this year.1234

Climb Bio's stock opened at $1.25 today, reaching a high of $1.39, but remains down 67% over the past year. Despite this, technical analysis currently favors a 'buy' signal. The company’s 52-week range is $1.05 to $5.86, reflecting ongoing volatility and investor uncertainty.53

Eliem Therapeutics has appointed Dr. Aoife Brennan as CEO and Dr. Jan Hillson as Senior Clinical Advisor following its Tenet Medicines acquisition. The company was also added to the Russell 2000 and 3000 indexes, boosting its profile among institutional investors and signaling a strategic shift toward autoimmune disease therapeutics.25